Trastuzumab pamirtecan, an investigational HER2-targeted antibody-drug conjugate, met the primary efficacy endpoint in a Phase 2 cohort of ...
Zacks Investment Research on MSN
Here's how AMRX is tapping GLP-1 demand through manufacturing
Amneal Pharmaceuticals AMRX has been steadily building a growth model that extends beyond traditional oral solid generics.
A cancer drug candidate that, rightly or wrongly, became a flashpoint at FDA, fails on a second try at approval.
New rules approved by Health Secretary Robert F. Kennedy Jr. could blunt the impact of a federal judge’s order freezing the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results